one nation – one biotech cluster · 2017. 1. 18. · - nobel biocare - novo nordisk competitive...
Post on 29-Jan-2021
2 Views
Preview:
TRANSCRIPT
-
One Nation – One Biotech Cluster
D. P. Alexakis – Swiss Biotech Association
-
SwissBiotech – Heading towards success !
«The Swiss industry is emerging as a sleeping giant and one to watchin coming years » Ernst & Young, 2002
« Switzerland … has a combined science citation intensity being higher than USA, UK and the other OECD countries »
David A. King, Nature, 15 July 2004, Science Magazine, 20004
« … Switzerland is probably one of the best places for biotech companies to establish themselves… »
Ernesto Bertarelli, SERONO International SA
-
Switzerland at a Glance
• 2004 was globally the 2nd best year in financing
• Record number of FDA approvals for biotech products
• Basilea was the 1st IPO since 2002 in Switzerland; more companies to come in the near future
• Switzerland ranks as number 6 in Europe
• and number 9 worldwide (since 1998)
• CHF 194 million of venture capital found its way into Swiss biotechs, which makes Switzerland rank as number 3 in Europe
• Total of 223 companies (4 less than 2003) which reflects some consolidation trends going on in the industry
• Still tough times for early stage, not product focused companies regarding financing
-
Swiss Biotech Association SBA (130 member companies)
The SBA intends to secure the position to which biotechnology SMEs willl be entitled now and in future. Focus is on:• Support to create the conditions in biotechnology appropriate
for SMEs. • Continue the awareness programme to reduce the fear
connected with modern biotechnology • Intensify research-related communication between universities
and the biotech industry • Promotion of the opportunities attached to professional careers
in science and biotechnology sector • Integration of the Swiss Biotech Industry on the national level,
on European level and on the global level.
-
Switzerland at a Glance – Tables / 1
Revenues, R&D expenses, Profits/losses
5473
1388
6791172
523
4296
986531
5032
0
1000
2000
3000
4000
5000
6000
Revenues R&D expenses Profits/losses
in C
HF
mio
200420032002
Source: Annual Reports and Website information / Ernst & Young
-
Switzerland at a Glance – Tables / 2
Number of Employees, Liquidity
13525
15902323
11648
2483
12846
0
2000
4000
6000
8000
10000
12000
14000
16000
Employees Liquidity
200420032002
Source: Annual Reports and Website information
in C
HF
mi o
-
Swiss Private Companies in 2005 / 1
Revenues, R&D expenses, Profits/losses
1549
350
22
345
22
1670
323
87
1596
0
200
400
600
800
1000
1200
1400
1600
1800
Revenues R&D expenses Profits/losses
in C
HF
mio
200420032002
Source: Ernst & Young
-
Swiss Public Companies in 2005 / 1
Revenues, R&D expenses, Profits/losses
3924
1038657
827501
2626
663444
3436
0
500
1000
1500
2000
2500
3000
3500
4000
4500
Revenues R&D expenses Profits/losses
in C
HF
mio
200420032002
Source: Annual Reports and Website information
-
Swiss Private Companies in 2005 / 2
Number of Employees, Liquidity (in CHF mio)
6063
462 426
4883
499
5926
0
1000
2000
3000
4000
5000
6000
7000
Employees Liquidity
200420032002
Source: Ernst & Young
-
Swiss Public Companies in 2005 / 2
Number of Employees, Liquidity (in CHF mio)
7462
11341897
6765
1984
6920
0
1000
2000
3000
4000
5000
6000
7000
8000
Employees Liquidity
200420032002
Source: Annual Reports and Website information
-
Number of Biotechs in Switzerland
133 139 129119 115
96 9388 87 86 88 8470
90
0
20
40
60
80
100
120
140
160
2004 2003 2002 2001 2000 1999 1998
Core Biotech Companies
Biotech suppliers
Source: Ernst & Young
-
Year of Company Foundation
9 11 8 715
821 16 12
5
111
0
20
40
60
80
100
120
2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 Before1995
Source: Ernst & Young
-
Activity Fields of Core Biotechs
18.8%
12.8%6.8%
7.5%
6.8%
5.3%
3.8%
3.0%1.5%
15.0%18.8% Receptor biology/signaling
Immunology
Screening
Chemistry
Drug Delivery
Cell or tissue culture
Proteomics/Metabolomics
Bioinformatics
Genomics/genetics
Bioprocess
OtherSource: Ernst & Young
-
European Public Companies Products Pipeline
2845514Denmark
3116816France
32010814Sweden
7911111245Switzerland
19423565065UK
TotalPhase IIIPhase IIPhase IPre-clinicalCountry
Source: Ernst & Young and BioCentury, 2003
-
Swiss Biotech – Summary Companies – size distribution :
• 6 public companies (globally active), such as Serono, Berna Biotech and Actelion ;
• 18 medium-sized companies with 50-100 employees(many of these more or less ready for IPO)
• 199 smaller companies with less than 50 employees
Influx of venture capital : 2001: CHF 106 million2002: CHF 148 million2003: CHF 130 million2004: CHF 194 million
• In 2002, 2003 and 2004 Switzerland ranked third in Europe regardingventure capital influx into the country.
-
One Nation – One Biotech Cluster
-
Compared to other European countriesSwitzerland is very attractive as
global headquarters locationAs % of all global headquarters that moved to these countries
Destination of global headquarters that moved
outside their country of origin
Source : National Authorities, trade organizations and Arthur D. Little desk research - 2002
-
Companies use very specific criteria to determine the appropriate
headquarters location88%
Corporate tax advantagesQualified managers
Quality of lifeCentral location
Support of authoritiesPersonal preference of CEO
International managersInternational schools
Language skillsLabor flexibility (no unions, Hire and Fire)
Ease of attracting top managersHigh purchasing power
High educationAttractive personal taxes
Image of the countryLabor availability
Proximity to existing production site
72%69%
62%55%
50%48%
37%35%35%
31%25%
22%19%
17%17%
10%
Most important criteriaused by companies for
the selection of headquarters location
Arthur D. Little - 2002
-
Ticino - Southern part of CH Biopolo Ticino (1/2)
· Main Industry- Chemical and pharmaceutical- Banking - Textile - Tourism
· Key Academic Institiutions- Università della Svizzera Italiana, Accademia di architettura, - University of Applied sciences- Institute for Research in Biomedicine- Istituto Oncologico della Svizzera Italiana- Istituto delle Molle per la ricerca sull’intelligenza artificiale- Centro Svizzero di Calcolo Scientifico
· Initiative: www.biopolo.ch
-
TicinoSouthern part of CH Biopolo Ticino (2/2)
· Specialities- Strong manufacturing cluster- Strong clinical settings (public and private)
· „Flagships“ (selection)- Helsinn SA, IBSA SA - KerrHawe SA, Medacta SA- Jetpharma SA, Micromacinazione SA- Start-ups:
• Mondobiotech SA• Oncore therapeutics SA
· Competitive Advantages- Competitive position for research in human immunology- Proximity to Italy- Quality of life
-
BioValley Basel (2/2)
Specialities- International conferences – BioSquare 2004, MipTec, ECB11th, etc.- lectures / BioTech roundtables- access to trinational Life Sciences Network in France, Germany and
Switzerland- BioValley Journal (www.biovalley.com)
„Flagships“(selection)- Actelion Pharmaceutical Ltd.- Basilea Pharmaceutica AG (IPO in March 2004)- Hesperion- RCC, Solvias, Speedel, etc.
Competitive Advantages- BioValley (cross-border) initiative- “big pharma” connections- High concentration of science and engineering community
-
BioValley Basel (1/2)
Main Industry - Life Sciences: Novartis, Roche, Aventis, Syngenta, Lonza- Chemistry: Ciba Specialty Chemicals, Clariant- Logistics: Danzas, Panalpina, Rhenus
Key Academic Institutions- Universities of Basel, Biocenter/Pharmacenter- Department of clinical-biological sciences (DKBW)- National Nanotechnology Center of Competences in Research (NCCR)- European Center of Pharmaceutical Medicine (ECPM)- As from 2006: ETH Institute for systemsbiology- Friedrich Miescher Institute (FMI)- Swiss Tropical Institute- Universities of Mulhouse, Freiburg, Strasbourg
Initiative: www.biovalley.com
-
Greater Zurich AreaZurich MedNet (1/2)
Main Industry- (Mechanical) Engineering- Services- Banking
Key Academic Institutions- University of Zurich- Federal Institute of Technology (ETHZ)- Universities of Applied Sciences (Wädenswil, Winterthur)- University Hospital- Neuroscience Center- Functional Genomics Center
Initiative: www.zurichmednet.org
-
Greater Zurich Area / Zurich MedNet (2/2)
Specialities- LifeSciene Incubator - Biotop- LifeScience Park Zurich-Schlieren- Conferences and Life Sciene seminars- Focused Investement conferences
„Flagships“(selection)- Cytos Biotechnology- ESBATech- Prionics- SWX – Swiss Exchange- Nobel BioCare- Novo Nordisk
Competitive Advantages- global initiative- virtual network- financial community
-
Lake Geneva Area / BioAlps (1/2)
Main Industry- Microelectronics - Watches- Private Banking
Key Academic Institiutions- University of Geneva / Lausanne (HUG/CHUV)- Swiss Federal Institute of Technology (EPFL)- Swiss Institute for Cancer Research Ludwig Institute- Swiss Institute for Bioinformatics- ISREC, Lausanne
Initiative: www.bioalps.com
-
Lake Geneva Area / BioAlps (2/2)
Specialities- Geneva Proteomics (GeneProt)- joint efforts of academic institutions in Life Sciences- scientific parks / incubators
„Flagships“ (selection)- Serono International Ltd.- Modex Therapeutics- NovImmune- Medtronic- GeneBio, Covance
Competitive Advantages- multi-disciplinary research activities- international environment- quality of life
-
National Strengths through competent information
• Database with over 1000 Swiss contacts
• Organizations active in the Life Sciences area
• Main focus on Biotechnology
Biotechnology related
Biotechnology Instrumentation& Services
Biotechnology
MedicalTechnology
Non-profitOrganization
Supplier
Consulting Investor
www.swisslifesciences.ch
-
Swiss Biotech Association SBA (130 member companies)European Public Companies Products PipelineSwiss Biotech ? SummaryTicino - Southern part of CH Biopolo Ticino (1/2)TicinoSouthern part of CH Biopolo Ticino (2/2)BioValley Basel (2/2)BioValley Basel (1/2)Greater Zurich AreaZurich MedNet (1/2)Greater Zurich Area / Zurich MedNet (2/2)Lake Geneva Area / BioAlps (1/2)Lake Geneva Area / BioAlps (2/2)
top related